Preventing infective complications in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Infectious Disease

Background:

• Treatment for inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, has evolved with increased use of immunosuppressives and biologics.
• These advanced therapies improve clinical outcomes but elevate the risk of serious, opportunistic infections in IBD patients.
• Managing this risk requires balancing disease control with infection prevention strategies, similar to monitoring for malignancy.

Purpose of the Study:

• To review evidence and guidelines for physicians managing IBD patients on immunomodulating agents.
• To provide strategies for preventing opportunistic infections in this patient population.

Main Methods:

• Literature review of current evidence and clinical guidelines.
• Synthesis of information on immunosuppressive and biologic therapies in IBD.
• Analysis of infection risks and prevention strategies.

Main Results:

• Immunosuppressive and biologic therapies are increasingly used earlier and longer for IBD, improving outcomes.
• Increased use of these therapies correlates with a higher risk of preventable opportunistic infections.
• A balance between therapeutic benefit and infection risk is achievable through physician expertise and patient engagement.

Conclusions:

• Physicians must carefully select and monitor immunomodulating therapies for IBD patients.
• Patient education on infection risk and prevention is crucial for minimizing serious infections.
• Proactive management strategies can mitigate the infectious risks associated with modern IBD treatments.